Our LPT-CBD injection offers a new approach to managing chronic pain in companion animals. This innovative single injection solution provides long-lasting drug exposure and effective relief, improving the quality of life for pets.
Addressing a Growing Market
The veterinary pain management market, currently valued at $1.65 billion, is projected to exceed $2.2 billion by 2029. Companion animals represent the largest segment, comprising 85% of this market. Our innovative LPT-CBD injection is well-positioned to address the needs of this growing market.
Efficacy and Safety
Our LPT-CBD technology has demonstrated significant efficacy and preliminary safety in pre-clinical studies focused on chronic pain conditions in companion animals:
- Osteoarthritis and cervical pain in a dog: As part of compassionate care, a single subcutaneous injection of LPT-CBD improved pain and activity for up to 3 weeks
- Osteoarthritis-related Pain in dogs: A single subcutaneous injection of LPT-CBD provided long-term analgesic effects, lasting several weeks
- Pharmacokinetics in dogs: A single LPT-CBD injection maintained CBD plasma concentrations for up to 6 weeks
- Preliminary Safety in dogs: Safety monitoring, including vital signs, hematology, and serum biochemistry, showed favorable safety profile and good drug-tolerance
Regulatory Progress
FDA’s Center for Veterinary Medicine (CVM) assigned an Investigational New Animal Drug (INAD) number for LPT-CBD that facilitates LPT-CBD development as a new veterinary drug regulatory pathway.
Commitment to Animal Health
At Innocan, we are dedicated to improving the lives of companion animals through scientific innovation. Our LPT-CBD technology addresses real clinical needs, providing significant pain relief for pets with chronic pain.
Discover how Innocan is making strides in veterinary pain management with our LPT-CBD injection.
